Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 310 • 2012 ACR/ARHP Annual Meeting
STAT3 Plays a Central Role in NLRP3 Inflammasome-Mediated IL-1β Production and Pyronecrosis
Jehad H. Edwan¹, Tri M. Tran², Mones Abu-Asab³, Raphaela T. Goldbach-Mansky⁴ and Robert A. Colbert¹, ¹NIAMS NIH, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD, ³NEI NIH, Bethesda, MD, ⁴Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose: Gain of function mutations in NLRP3 cause cryopyrin-associated periodic fever syndromes (CAPS), the most severe form of which is neonatal-onset multisystem inflammatory disease (NOMID),…
Abstract Number: 2485 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor: Analyses of Efficacy and Safety of 10 versus 5mg Twice Daily in a Pooled Phase 3 and Long-Term Extension Rheumatoid Arthritis Population
S. Cohen¹, S. Krishnaswami², B. Benda³, R. Riese², M.G. Boy⁴, D. Gruben⁴, G. Wallenstein⁵, C. A. Mebus⁴, S. H. Zwillich² and J. D. Bradley⁶, ¹Metroplex Clinical Research Centre, Dallas, TX, ²Pfizer Inc., Groton, CT, ³Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Phase (P) 3 studies demonstrated…
Abstract Number: 2326 • 2012 ACR/ARHP Annual Meeting
Discovery of a Highly Potent, Selective Reversible Covalent Inhibitor of JAK3 Kinase
Ronald J. Hill¹, Angelina Bisconte¹, J. Michael Bradshaw¹, Ken Brameld², Eun Ok Kim¹, Xiaoyan Li², Tim Owens², Erik Verner² and David M. Goldstein², ¹Biology, Principia Biopharma, South San Francisco, CA, ²Chemistry, Principia Biopharma
Background/Purpose: Targeting of the JAK-STAT pathway has been shown to be efficacious for treatment of patients with rheumatoid arthritis through the successful use of pan-JAK…
Abstract Number: 2150 • 2012 ACR/ARHP Annual Meeting
Action of Tofacitinib Via Human Dendritic Cells
Satoshi Kubo¹, Kunihiro Yamaoka², Shigeru Iwata¹ and Yoshiya Tanaka¹, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Tofacitinib, an oral Janus Kinase (JAK) inhibitor, has gathered attention in treatment of Rheumatoid arthritis (RA). Although JAKs are well known for its importance…
Abstract Number: 2084 • 2012 ACR/ARHP Annual Meeting
ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats
Shunji Yamazaki¹, Masamichi Inami¹, Misato Ito¹, Yasutomo Fujii¹, Kaori Hanaoka¹, Kaoru Yamagami¹, Kenji Okuma¹, Yoshiaki Morita¹, Shohei Shirakami², Takayuki Inoue², Susumu Miyata³ and Yasuyuki Higashi¹, ¹Pharmacology Research Labs, Astellas Pharma Inc., Tsukuba, Japan, ²Chemistry Research Labs, Astellas Pharma Inc., Tsukuba, Japan, ³Research Planning & Administration, Astellas Pharma Inc., Tsukuba, Japan
Background/Purpose: The Janus kinase (JAK) family of enzymes plays a key role in cytokine signaling, which is involved in the pathogenic events of immune-mediated disorders…
Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials
Sima Ahadieh¹, Tina Checchio¹, Thomas Tensfeldt¹, Jonathan French², Sriram Krishnaswami¹, Richard Riese³, Sujatha Menon¹, Mary G. Boy¹ and Jamie L. Geier⁴, ¹Pfizer Inc., Groton, CT, ²Metrum Research Institute, Tariffville, CT, ³Pfizer Inc, Groton, CT, ⁴Epidemiology, Pfizer Inc., New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…
Abstract Number: 1322 • 2012 ACR/ARHP Annual Meeting
Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis
Tong Zhu¹, Kazuo Oda², Udaya Valluri¹, Bogie Moore¹, Ying Cao¹, Vishala Chindalore³ and Bola Akinlade⁴, ¹Astellas Pharma Global Development, Inc., Northbrook, IL, ²Drug Metabolism Research Labs. Drug Discovery Research, Astellas Pharma Inc., Osaka, Japan, ³Pinnacle Research Group/Anniston Medical Clinic, Anniston, AL, ⁴Immunology Development, Astellas Pharma Global Development, Inc., Northbrook, IL
Background/Purpose: ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid arthritis (RA) and other autoimmune diseases.…
Abstract Number: 1297 • 2012 ACR/ARHP Annual Meeting
Tofacitinib and Adalimumab Achieve Similar Rates of Low Disease Activity in Rheumatoid Arthritis — Lack of Improvement in Disease Activity Score by 3 Months Predicts Low Likelihood of Low Disease Activity At 1 Year
Ronald F. van Vollenhoven¹, Sriram Krishnaswami², Birgitta Benda³, David Gruben⁴, Bethanie Wilkinson⁴, Charles A. Mebus⁴, Samuel H. Zwillich² and John Bradley², ¹Karolinska Institute, Stockholm, Sweden, ²Pfizer Inc, Groton, CT, ³Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This post-hoc analysis of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].